Why NeuBase Therapeutics Popped by 16.5% on Friday
NeuBase Therapeutics (NASDAQ: NBSE) ended the week on a real sugar high, rising by nearly 17% on Friday. This was due to a glowing note about the biotech from one of its more prominent investors.
The praise came from Greenlight Capital, the hedge fund run by noted investor David Einhorn. On Thursday, Greenlight released the latest quarterly update on its performance.
As is its habit, Greenlight dived into the particulars of several portfolio investments, among which was NeuBase. Greenlight waxed enthusiastic about the company's PATrOL platform, a cutting-edge technology which modifies the protein function of genes in order to precisely target diseases.
Source Fool.com
